Stem Cell Study

Title: A Double-Blind, Controlled Phase 2B Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients with Chronic Motor Deficit from Ischemic Stroke

Status: Enrollment closed as of October 2017

Sponsor: San Bio/Sanovian Pharmaceuticals  (Commercial) 

PI: Richard Zorowitz 

Primary Outcome Measure: Fugl-Meyer Motor Scale

Secondary Outcome Measures: Modified Ranken; Action Research Arm Test; Gait Velocity

Go to for more details